{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T11:28:21Z","timestamp":1793618901188,"version":"4.5.0"},"reference-count":14,"publisher":"Walter de Gruyter GmbH","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2026-0469_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Traditional urine immunofixation electrophoresis (uIFE) is cumbersome, has limited sensitivity, and is subjectively interpreted. This is especially problematic in renal impairment where accumulation of polyclonal free light chains may pseudonormalize the serum free light chain (sFLC) ratio, compromising its reliability for disease monitoring. This study aimed to validate two MALDI-TOF mass spectrometry (MS)-based methods for urinary M-protein detection and to evaluate their clinical utility, particularly in addressing this limitation of sFLC ratio interpretation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0469_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In 325 patients with multiple myeloma or amyloidosis, we compared two conventional uIFE methods (uIFE and uIFE-FLC) with two novel MALDI-TOF MS methods (iMS-IP Assay-urine and iMS-FLC Assay-urine). Patients were divided into a uIFE-positive cohort (164 cases) and a uIFE-negative cohort (161 cases). We evaluated the agreement between the novel methods and serological evidence (serum immunofixation electrophoresis [IFE] and sFLC), as well as their performance in challenging scenarios including renal impairment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0469_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The iMS-IP Assay-urine showed excellent agreement with uIFE (94.46\u202f%, \u03ba=0.877) and detected additional M-protein-positive cases that correlated with serum findings. The iMS-FLC Assay-urine showed moderate agreement with uIFE-FLC (80\u202f%, \u03ba=0.615) and detected significantly more positive cases, with support from serum assays. Notably, in six seronegative patients with renal impairment, iMS-FLC Assay-urine detected monoclonal free light chains in all cases, whereas uIFE-FLC detected only three. Both mass spectrometry methods also provided N-glycosylation information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0469_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The iMS-IP and iMS-FLC urine assays are sensitive, rapid, and objective, outperforming conventional uIFE. They offer critical complementary information, particularly in seronegative patients with renal impairment, supporting their potential to replace traditional urine immunofixation electrophoresis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2026-0469","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:55:56Z","timestamp":1785239756000},"page":"2895-2904","source":"Crossref","is-referenced-by-count":0,"title":["Performance validation of mass spectrometry for detecting urinary Bence Jones protein and evaluation of its clinical application in multiple myeloma and amyloidosis"],"prefix":"10.1515","volume":"64","author":[{"given":"Yu","family":"Chen","sequence":"first","affiliation":[{"name":"Zhejiang Chinese Medical University , Hangzhou , Zhejiang , China"},{"name":"Department of Hematology , The First Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , Zhejiang , China"},{"name":"Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment , Hangzhou , Zhejiang , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Wang","sequence":"additional","affiliation":[{"name":"Intelligene Biosystems (Qingdao) Co., Ltd. , Qingdao , Shandong , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziliang","family":"Zhong","sequence":"additional","affiliation":[{"name":"Intelligene Biosystems (Qingdao) Co., Ltd. , Qingdao , Shandong , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuling","family":"Ma","sequence":"additional","affiliation":[{"name":"The Second School of Clinical Medicine , Henan University of Chinese Medicine , Zhengzhou , Henan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Hematology , The First Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , Zhejiang , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology , The First Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , Zhejiang , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Li","sequence":"additional","affiliation":[{"name":"Zhejiang Chinese Medical University , Hangzhou , Zhejiang , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"2026110211032921872_j_cclm-2026-0469_ref_001","doi-asserted-by":"crossref","unstructured":"Rajkumar, SV, Dimopoulos, MA, Palumbo, A, Blade, J, Merlini, G, Mateos, MV, et al.. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538\u201348. https:\/\/doi.org\/10.1016\/s1470-2045(14)70442-5.","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"2026110211032921872_j_cclm-2026-0469_ref_002","doi-asserted-by":"crossref","unstructured":"Willrich, MA, Katzmann, JA. Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias. Clin Chem Lab Med 2016;54:907\u201319. https:\/\/doi.org\/10.1515\/cclm-2015-0580.","DOI":"10.1515\/cclm-2015-0580"},{"key":"2026110211032921872_j_cclm-2026-0469_ref_003","doi-asserted-by":"crossref","unstructured":"Kumar, S, Paiva, B, Anderson, KC, Durie, B, Landgren, O, Moreau, P, et al.. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328\u201346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6.","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"2026110211032921872_j_cclm-2026-0469_ref_004","doi-asserted-by":"crossref","unstructured":"Dimopoulos, M, Kyle, R, Fermand, JP, Rajkumar, SV, San Miguel, J, Chanan-Khan, A, et al.. Consensus recommendations for standard investigative workup: report of the international myeloma workshop consensus panel 3. Blood 2011;117:4701\u20135. https:\/\/doi.org\/10.1182\/blood-2010-10-299529.","DOI":"10.1182\/blood-2010-10-299529"},{"key":"2026110211032921872_j_cclm-2026-0469_ref_005","doi-asserted-by":"crossref","unstructured":"Singh, G, Arinze, N, Manthei, DM, Plapp, FV, Bollag, RJ. Urine protein immunofixation electrophoresis: free light chain urine immunofixation electrophoresis is more sensitive than conventional assays for detecting monoclonal light chains and could serve as a marker of minimal residual disease. Lab Med 2023;54:527\u201333. https:\/\/doi.org\/10.1093\/labmed\/lmac155.","DOI":"10.1093\/labmed\/lmac155"},{"key":"2026110211032921872_j_cclm-2026-0469_ref_006","doi-asserted-by":"crossref","unstructured":"Rosanky, SJ, Sartiano, GP, Lynch, B, Gonzales, F, Valdivieso, J. Bence Jones proteinuria. N\u00a0Engl J Med 1982;307:1026\u20137. https:\/\/doi.org\/10.1056\/NEJM198210143071620.","DOI":"10.1056\/NEJM198210143071621"},{"key":"2026110211032921872_j_cclm-2026-0469_ref_007","doi-asserted-by":"crossref","unstructured":"Mills, JR, Kohlhagen, MC, Dasari, S, Vanderboom, PM, Kyle, RA, Katzmann, JA, et al.. Comprehensive assessment of M-Proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry. Clin Chem 2016;62:1334\u201344. https:\/\/doi.org\/10.1373\/clinchem.2015.253740.","DOI":"10.1373\/clinchem.2015.253740"},{"key":"2026110211032921872_j_cclm-2026-0469_ref_008","doi-asserted-by":"crossref","unstructured":"Derman, BA, Yee, AJ. Clinical applications of mass spectrometry in multiple myeloma. Blood Adv 2025;9:6593\u2013603. https:\/\/doi.org\/10.1182\/bloodadvances.2024015685.","DOI":"10.1182\/bloodadvances.2024015685"},{"key":"2026110211032921872_j_cclm-2026-0469_ref_009","doi-asserted-by":"crossref","unstructured":"Moonen, DH, Kohlhagen, M, Dasari, S, Willrich, MA, Kourelis, T, Dispenzieri, A, et al.. Utilizing mass spectrometry to detect and isotype monoclonal proteins in urine: comparison to electrophoretic. Methods Clin Chem 2023;69:746\u201353. https:\/\/doi.org\/10.1093\/clinchem\/hvad053.","DOI":"10.1093\/clinchem\/hvad053"},{"key":"2026110211032921872_j_cclm-2026-0469_ref_010","doi-asserted-by":"crossref","unstructured":"Molina-And\u00fajar, A, Robles, P, Cibeira, MT, Montagud-Marrahi, E, Guillen, E, Xipell, M, et al.. The renal range of the \u03ba\/\u03bb sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease. BMC Nephrol 2020;21:111. https:\/\/doi.org\/10.1186\/s12882-020-01771-3.","DOI":"10.1186\/s12882-020-01771-3"},{"key":"2026110211032921872_j_cclm-2026-0469_ref_011","doi-asserted-by":"crossref","unstructured":"Long, TE, Indridason, OS, Palsson, R, Rognvaldsson, S, Love, TJ, Thorsteinsdottir, S, et al.. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study. Blood Cancer J 2022;12:133. https:\/\/doi.org\/10.1038\/s41408-022-00732-3.","DOI":"10.1038\/s41408-022-00732-3"},{"key":"2026110211032921872_j_cclm-2026-0469_ref_012","doi-asserted-by":"crossref","unstructured":"Xu, L, Zhao, B, Sun, Y, Wang, S, Chen, X, Mao, Y. Using two detection methods to observe the changes and significance of free light chain in serum and urine in patients with renal insufficiency. Biomed Res Int 2022;2022:5536199. https:\/\/doi.org\/10.1155\/2022\/5536199.","DOI":"10.1155\/2022\/5536199"},{"key":"2026110211032921872_j_cclm-2026-0469_ref_013","doi-asserted-by":"crossref","unstructured":"Chen, Y, You, L, Zhu, L, Yin, X, Yao, Q, Ding, S, et al.. Evaluation of iMS-IP assay for the detection and typing of monoclonal immunoglobulins. Clin Chim Acta 2026;581:120756. https:\/\/doi.org\/10.1016\/j.cca.2025.120756.","DOI":"10.1016\/j.cca.2025.120756"},{"key":"2026110211032921872_j_cclm-2026-0469_ref_014","doi-asserted-by":"crossref","unstructured":"Bridoux, F, Leung, N, Nasr, SH, Jaccard, A, Royal, V. International kidney and monoclonal gammopathy research group. Kidney disease in multiple myeloma. Presse Med 2025;54:104264.","DOI":"10.1016\/j.lpm.2024.104264"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0469\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0469\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T11:07:27Z","timestamp":1793617647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0469\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":14,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,7,28]]},"published-print":{"date-parts":[[2026,11,25]]}},"alternative-id":["10.1515\/cclm-2026-0469"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2026-0469","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]}}}